Literature DB >> 450566

Evidence for hypertyraminemia in Reye's syndrome.

B A Faraj, S L Newman, D B Caplan, F M Ali, V M Camp, P A Ahmann.   

Abstract

Utilizing a specific and sensitive radioimmunoassay, palsma and urine tyramine were measured in 14 consecutive patients with liver biopsy-proven Reye's syndrome. Plasma tyrosine was measured in 11 of these patients. The results revealed significant (P less than .003) elevation in plasma (3.4 +/- .52 ng/ml) (mean +/- SEM) and urine (1.00 +/- .26 mg/24 hr) tyramine as well as plasma tyrosine (204 +/- 52.5 mumole/liter) at the onset of the disease when compared to the levels of tyramine and tyrosine in a group of hospitalized patients without hepatic disorders. Furthermore, there was a positive correlation between plasma tyramine and days in coma (r = .86; P less than .001), and between plasma tyramine and tyrosine (r = 0.80; P less than .001). These data suggest that there is s substantial disturbance of tyrosine metabolism in Reye's syndrome and that the accumulation of this amino acid and its metabolite, tyramine, may contribute to the encephalopathy of this disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 450566

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

1.  Aflatoxin B1 alters central and systemic tryptophan and tyrosine metabolism: influence of immunomodulatory drugs.

Authors:  L B Weekley
Journal:  Metab Brain Dis       Date:  1991-03       Impact factor: 3.584

2.  Evidence for central hypertyraminemia in hepatic encephalopathy.

Authors:  B A Faraj; V M Camp; J D Ansley; J Scott; F M Ali; E J Malveaux
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

3.  Therapeutic aspirin overdose in a three-year-old boy.

Authors:  D C Brown; J M Savage
Journal:  Ulster Med J       Date:  1987-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.